PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany
Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1664
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2012
Authors
Publisher
Elsevier BV